Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
|Podcasts|August 21, 2020
Pharmacy Focus Episode 5: The Ever Changing Role of Emergency Medicine Pharmacists
The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.
Advertisement
In this week’s episode, we will be discussing emergency medicine pharmacists. Email your pharmacy hero nomination to AAntrim@pharmacytimes.com!
Advertisement
Related to this article
Twice-daily metronidazole dosing had outcomes comparable with those of thrice-daily dosing for confirmed anaerobic infections, minimizing drug exposure and cost while maintaining clinical efficacy.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
2
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
3
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
4
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
5